Extending the benefits of extreme precision technology to medical challenges
By constantly improving its digital endpoint platform, Sysnav Healthcare provides ever more accurate data through continuous and seamless patient monitoring thanks to a cutting-edge technology backed by more than 20 patents.
The magneto-inertial tachymeter (MIT) is a patented technology by Sysnav. Based on a unique approach that merges inertial data and terrestrial magnetic data, SYSNAV innovations, rewarded by the MIT Technology Review, have created a new generation of magneto-inertial technology that enables precise motion capture.
Our approach combines inertial sensor calibration and trajectory calculation algorithms, along with the integration of variations in the geomagnetic field to determine speed and deviation with greater accuracy.
Several inertial sensors in Syde continuously collect precise 3-dimensional data. The data are transmitted remotely to our servers, then analyzed by our algorithms to reconstruct movement trajectories as well as whole acts. Our data scientists use this information to identify relevant endpoints, allowing clinicians to analyze, compare and diagnose patient outcomes.
Since the very start of the company, SYSNAV has focused on innovation, scientific excellence, teamwork, discipline, creativity and the desire to find solutions to complex equations and to advance on unresolved projects where others have not succeeded yet. Scientific curiosity and the taste for strategic challenges guide our missions.
SYSNAV Healthcare was created by the meeting of neuromuscular physicians and experts in search of innovative tools to improve and accelerate researchers and French experts in motion capture, driven by the major scientific challenge to adapt the innovative and ground-breaking magneto inertial technology to useful fields.
Driven by humility and relentless desire to improve patient quality of life, the 30 engineers and experts of Sysnav Healthcare put strong partnerships with key health stakeholders (patient associations, scientific communities, physicians, regulators, pharmaceutical companies…) at the center of their approach to adapt in the most relevant way our technology to health challenges/to answer the needs of both science and patients. Through cooperation and scientific input, we aim to accelerate medical progress by improving clinical trials, facilitating strategic decisions, and opening the road to personalized medicine with reliable, precise, and meaningful real-world data.
SYSNAV Healthcare rewarded during the World Muscle Society Congress
SYSNAV Healthcare was rewarded at the World Muscle Society Congress 2021 ( (20.09.2021 - 24.09.2021) for its poster published by Margaux Poleur, a doctor from CHU de Liège based on the data and results of our ActiMyo device for SMA disease.
Neurodevelopmental drug development summit (14.12.2021 – 15.12.2021)
SYSNAV Healthcare will participate in this event as a solution provider, developing new outcome measures for rare neurodevelopmental disorders such as Angelman or Rett Syndrome. We will discuss the new challenges of clinical trial design.
By Yacine Bechichi